High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Richard S Finkel, Thomas O Crawford, Eugenio Mercuri, Charlotte J Sumner, Maria Del Mar Garcia Romero, John W Day, Jacqueline Montes, Peng Sun, Ben Tichler, Angela D Paradis, Emily Boesch, Jennifer Inra, Ross Littauer, Jihee Sohn, Michael Monine, Giulia Gambino, Richard Foster, Raechel Farewell, Stephanie Fradette
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 10 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Extended Data Fig. 1:AI 判定为 multi panel km;Extended Data Fig. 2:非 KM 图;另有 5 张未列出。
摘要
摘要
Despite the remarkable benefits of nusinersen and other disease-modifying therapies in spinal muscular atrophy (SMA), patients may still experience clinical manifestations of the disease. Here we assessed the potential for high-dose nusinersen to rapidly slow neurodegeneration and lead to improved outcomes for patients. The global, three-part, phase 2/3 DEVOTE trial evaluated the efficacy and safety of high-dose nusinersen (50-mg loading dose; 28-mg maintenance dose) in individuals with SMA. In Part B, treatment-naive individuals (n = 75) were randomized 2:1 to 50/28 mg or 12/12 mg nusinersen. In a supportive open-label cohort (Part C), nusinersen-experienced individuals (12/12 mg for more than 1 year) were enrolled. The primary endpoint (Part B infantile-onset participants) was a 6-month change in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score comparing 50/28 mg with matched ENDEAR participants (n = 20) who received sham. DEVOTE met its primary endpoint: at day 183, the CHOP-INTEND total score significantly improved (+15.1 points) in those who received 50/28 mg nusinersen and worsened (-11.1 points) in matched ENDEAR participants who received sham (difference, 26.19 (95% confidence interval = 20.7 to 31.74); statistical testing was performed using the joint-rank test where the difference in ranks was 26.06 (95% confidence interval = 17.9 to 34.2; P < 0.0001). The safety profile of 50/28 mg nusinersen was similar to the 12/12 mg regimen. The data support that high-dose nusinersen provides benefit in patients with SMA, with a generally well-tolerated safety profile. ClinicalTrials.gov registration: https://clinicaltrials.gov/study/NCT04089566 . EudraCT no: 2019-002663-10.
KM 提取结果
0 个 Figure · 0 个 KM 面板
尚未提取到 KM 面板。其他 Figure(10,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。
Fig. 1Parts B and C: patient disposition. The Part B cohort with infantile-onset SMA was compared with a matched group of 20 participants from ENDEAR who had received sham. The Part B cohort with later-onset SMA was compared with two matched groups of participants from CHERISH who had received sham ( n = 16) and 12/12 mg nusinersen ( n = 32).
非 KM Figure
Fig. 2Part B cohort with infantile-onset SMA: CHOP-INTEND (primary endpoint), NfL levels and EFS. a , The primary analysis was performed using ranking based on the CHOP-INTEND score at day 183 or day of death and fitting an ANCOVA model adjusting for disease duration and baseline CHOP-INTEND to determine the difference in ranks via the joint-rank test. MI was used to impute missing data. b , Results are from an ANCOVA model with adjustment for participants’ disease duration, baseline log plasma NfL and baseline CHOP-INTEND score. MI was used to impute missing data. In the table, the LSGM ratio from the ANCOVA is shown; the P value was determined using the joint-rank test. c , The P value was determined using the log-rank test stratified according to disease duration (≤12 weeks or >12 weeks). P values were obtained by comparing the two treatment groups indicated per row in each table above each chart. Comparisons between 50/28 mg and 12/12 mg, and between 50/28 mg and matched sham, were performed as separate analyses. In addition to the P value, rankings, changes from baseline in actual scores and ratios are shown. For the EFS and OS, comparisons were similarly made between the two treatment groups. Because of hierarchical testing, none of the time-to-event endpoints were considered statistically significant. Where P < 0.05 but hierarchical testing had stopped, the P value was considered nominally significant and is denoted. a P value was considered nominally significant. Study day 1 was the baseline. All statistical tests were two-sided. LSGM, least-squares geometric mean.
非 KM Figure
Fig. 3Part B cohort with later-onset SMA: HFMSE and RULM. Data in the tables represent the mean (s.d.). a , c , Study day 1 was the baseline and MI was used for missing data. b , d , Data were based on MI and ANCOVA with treatment as a fixed effect and adjustment for each participant’s age at first dose, baseline log plasma NfL and baseline HFMSE or RULM score. CHERISH matched 12/12 mg and sham groups indicate prespecified subsets of participants matched to the characteristics of the DEVOTE 50/28 mg group. Analysis days 183 and 279 in DEVOTE correspond with days 169 and 274 in CHERISH, respectively.
非 KM Figure
Extended Data Fig. 1Part B infantile-onset cohort – HINE-2. Study day 1 is baseline. All P values were obtained from comparing the two treatment groups indicated per row in each table above each chart. In the treatment columns, rankings and changes from baseline in actual scores are shown; the LSM differences correspond to the differences between the two listed treatments. Results shown are from ANCOVA model with adjustment for participants’ disease duration, baseline HINE-2 score and baseline CHOP-INTEND score. Missing data was handled with multiple imputation. All statistical tests were two sided. ANCOVA, analysis of covariance; CHOP-INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE-2, Hammersmith Infant Neurological Exam section 2; LSM, least-squares mean; MI, multiple imputation; SE, standard error.
非 KM Figure
Extended Data Fig. 2Part B infantile-onset cohort – CHOP-INTEND. a P value considered nominally significant. Study day 1 is baseline. All P values were obtained from comparing the two treatment groups indicated per row in each table above each chart. In the treatment columns, rankings and changes from baseline in actual scores are shown; the LSM differences correspond to the differences between the two listed treatments. Results shown are from an ANCOVA model with adjustment for participants’ disease duration and baseline CHOP-INTEND score. Missing data was handled with multiple imputation. All statistical tests were two sided. ANCOVA, analysis of covariance; CHOP-INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; CI, confidence interval; JRT, joint-rank test; LSM, least-squares mean; MI, multiple imputation; SE, standard error.
非 KM Figure
Extended Data Fig. 3Part B infantile-onset – Overall survival. a Indicates nominal significance; P value is from log-rank test stratified by disease duration ( ≤12 weeks or >12 weeks). All P values were obtained from comparing the two treatment groups indicated per row in each table above each chart. Due to the hierarchical testing, none of the time-to-event endpoints were considered statistically significant. Where a P value was <0.05 but hierarchical testing had stopped, the P value was considered nominally significant and is denoted (a). All statistical tests were two sided. CI, confidence interval; EFS, event-free survival; HR, hazard ratio.
非 KM Figure
Extended Data Fig. 4Part B later-onset cohort – Plasma NfL levels. a Indicates nominal significance. Study day 1 is baseline. The P value is obtained from comparing the two treatment groups indicated. In the treatment columns, the LSGM ratio to baseline is shown; the LSGM ratio corresponds to the difference between the two listed treatments. Results shown are from an ANCOVA model with adjustment for age at screening, baseline log plasma NfL and baseline HFMSE. Missing data was handled with multiple imputation. All statistical tests were two sided. ANCOVA, analysis of covariance; CI, confidence interval; LSGM, least-squares geometric mean; MI, multiple imputation; NfL, neurofilament light chain.
非 KM Figure
Extended Data Fig. 5Part C – HFMSE (A) and RULM (B). Study day 1 is baseline. Observed data and mean change are shown. Two participants did not have HFMSE/RULM scores collected at baseline and are not included in the analysis. HFMSE, Hammersmith Functional Motor Scale Expanded; RULM, Revised Upper Limb Module; SD, standard deviation; SE, standard error.
非 KM Figure
Extended Data Fig. 6Parts B and C – Study design. DEVOTE was powered to assess the efficacy of the 50/28 mg regimen in infantile-onset participants as compared to a prespecified matched sham group from ENDEAR. Inclusion of the 12/12 mg dosing regimen in Part B was intended to provide supportive evidence, but the study was not sufficiently powered to detect statistically significant differences between the 50/28 mg and 12/12 mg groups. a A prespecified hierarchical testing procedure was used for the primary and secondary endpoints for Part B infantile-onset (see Extended Data Table 2 ). b ENDEAR matched sham, CHERISH matched sham and CHERISH matched 12/12 mg indicate prespecified subsets of participants matched to characteristics of the DEVOTE 50/28 mg group (see Extended Data Table 2 ). CHOP-INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; EFS, event-free survival; HFMSE, Hammersmith Functional Motor Scale Expanded; HINE-2, Hammersmith Infant Neurological Exam section 2; NfL, neurofilament light chain; OS, overall survival; RULM, Revised Upper Limb Module; SMA, spinal muscular atrophy; SMN2, survival motor neuron 2 .
非 KM Figure
Extended Data Fig. 7Part B infantile-onset cohort – CHOP-INTEND sensitivity analyses. CHOP-INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; CI, confidence interval; ITT, intent-to-treat; LS, least-squares; MI, multiple imputation; PP, per protocol.